Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The role of regulated necrosis in endocrine diseases


The death of endocrine cells is involved in type 1 diabetes mellitus, autoimmunity, adrenopause and hypogonadotropism. Insights from research on basic cell death have revealed that most pathophysiologically important cell death is necrotic in nature, whereas regular metabolism is maintained by apoptosis programmes. Necrosis is defined as cell death by plasma membrane rupture, which allows the release of damage-associated molecular patterns that trigger an immune response referred to as necroinflammation. Regulated necrosis comes in different forms, such as necroptosis, pyroptosis and ferroptosis. In this Perspective, with a focus on the endocrine environment, we introduce these cell death pathways and discuss the specific consequences of regulated necrosis. Given that clinical trials of necrostatins for the treatment of autoimmune conditions have already been initiated, we highlight the therapeutic potential of such novel therapeutic approaches that, in our opinion, should be tested in endocrine disorders in the future.


Endocrine glands control the human body’s metabolism, vital functions, mental and physical adaptation to stress, and the capacity to reproduce. Regulated cell necrosis and cell proliferation define endocrine tissue development and homeostasis, as well as its capacity to adapt to stress and to prevent tumour formation. The term regulated cell death was used mostly synonymously with apoptosis until 15 years ago. However, our understanding of necrosis as a regulated process has dramatically expanded since then. In the past 15 years, we have begun to understand the details of necroptosis, pyroptosis and ferroptosis1. Necrosis not only causes organ dysfunction but also results in an inflammatory response driven by damage-associated molecular patterns (DAMPs), which is referred to as necroinflammation2,3.

Studies have shown that the three pathways of regulated necrosis, namely necroptosis, pyroptosis and ferroptosis, can be therapeutically targeted4,5,6. Accumulating data suggest that necroinflammation is of central relevance in the pathophysiology of endocrine disorders7,8, including septic adrenal dysfunction, autoimmune diseases such as type 1 diabetes mellitus (T1DM)9 and endocrine malignancies. Both the prevention of cell death by rescuing cells that otherwise succumb to necrosis (as is the case in T1DM)9 and the induction of necrosis in endocrine cancers (such as with adrenocortical carcinomas)10 might lead to therapeutic benefits. This Perspective therefore aims to summarize the existing data on the newly characterized cell death pathways in endocrine disorders while focusing on unanswered questions. We also discuss the need to revisit the literature that was published before the identification of necroptosis, pyroptosis and ferroptosis and reinterpret it in the light of the current understanding to highlight the possibility of therapeutic interventions.

The types of regulated cell death

Apoptosis: well defined and well tolerated by the immune system

Apoptosis (Fig. 1a) is the default cell death pathway for homeostasis and cellular turnover during physiological metabolism11,12. The caspase-controlled system results in the typical morphological features such as rapid shrinking of the cell, nuclear condensation, DNA fragmentation, exposure of phosphatidylserine and a process known as membrane blebbing11,12. Phosphatidylserine exposure functions as an ‘eat me’ signal to macrophages13,14,15. Importantly, the plasma membrane remains intact in apoptotically dying cells, a mechanism that prevents the release of intracellular content to the interstitial and/or extracellular space. Therefore, apoptosis is immunologically silent. The detection of apoptosis has been misinterpreted for decades by the TdT-mediated dUTP-biotin nick end-labelling (TUNEL) method (Box 1).

Fig. 1: Regulated cell death pathways at a glance.

Apoptosis represents a non-inflammatory pathway that is mediated by caspases (part a). Two distinct signalling pathways of apoptosis, extrinsic and intrinsic apoptosis, have been characterized. While apoptosis depends on the activation of caspases, necroptosis is mediated by kinases (part b). Dependent on its RHIM domain, RIPK3 forms an amyloid-like structure referred to as the necrosome, the central signalling platform of necroptosis. Therein, RIPK3 phosphorylates the pseudokinase MLKL. By unknown mechanisms, the phosphorylated form of MLKL (pMLKL) triggers plasma membrane rupture, a process that was demonstrated to be counteracted by the membrane repair ESCRT-III complex. In contrast to apoptosis and necroptosis, inflammasomes are involved in the initiation of cell death by pyroptosis (part c). The activation of caspases (1, 4, 11) in inflammasomes results in the cleavage of pro-IL-1β, pro-IL-18 and gasdermin D (GSDMD). Finally, and without any clear connection to apoptosis, necroptosis and pyroptosis, ferroptosis is a failsafe rather than a typical cell death pathway (part d). In cellular homeostasis, H2O2 concentrations of iron-catalysed and Fenton reactions are limited by diverse cellular anti-redox systems. Glutathione peroxidase 4 (GPX4) prevents lipid peroxidation that otherwise leads to plasma membrane rupture by unknown mechanisms. By contrast, the oxidoreductase FSP1 (also known as AIFM2) prevents lipid peroxidation upon myristoylation-dependent recruitment to the plasma membrane in a GSH-independent manner. casp, caspase; DAMP, damage-associated molecular pattern; DD, death domain; DED, death effector domain; ER, endoplasmic reticulum; FA, fatty acid; PL-OH, phospholipid alcohol; PL-OOH, phospholipid hydroperoxide; RTA, radical-trapping antioxidant.

Mechanistically, extrinsic apoptosis is mediated by death receptors such as tumour necrosis factor receptor 1 (TNFR1) or the FAS receptor (also known as CD95)16. To kill a cell through a TNFR1 signal, upon binding of the ligand TNF, the TNFR1 signalling complex dissociates from the plasma membrane. Within the cytosol, the FAS-associated death domain protein (FADD)-bound initiator caspase 8 is recruited to the complex and interacts with receptor-interacting protein kinase 1 (RIPK1)17,18. In the case of TNFR1, however, the default signal to activate the transcription factor NF-κB is maintained through the recruitment of kinases (IKKε and TBK1) through linear polyubiquitin chains on RIPK1 (ref.19) and does not result in cell death. Mechanistically, TBK1 phosphorylates RIPK1 and thereby inhibits its autophosphorylation-induced activation, which is required for cell death. However, upon activation of caspase 8, RIPK1 activity is prevented by proteolytic cleavage of RIPK1 by caspase 8 (ref.20). The proteolytically active caspase 8 also cleaves the effectors caspase 3, caspase 6 and caspase 7 (ref.21), which mediate the apoptotic cellular phenotype. As caspase 8 also controls the activation of the pyroptosis pathway22, it must be interpreted as the master regulator of death receptor-mediated cell death. The control of extrinsic apoptosis and necroptosis (which is discussed in the next section) by post-translational modification is reviewed in more detail elsewhere23,24,25.

By contrast, loss of the mitochondrial outer membrane potential and the recruitment of BAX and BAK to the outer mitochondrial membrane result in the release of mitochondrial content into the cytosol26. For instance, cytochrome c assembles with the cytosolic proteins APAF1 and caspase 9, which results in the formation of the apoptosome, a large heteroheptameric structure that activates the effectors caspase 3, caspase 6 and caspase 7 to execute intrinsic apoptosis27,28,29.

Necroptosis: MLKL-mediated necrosis to defend viruses

Necroptosis is thought to be evolutionarily conserved as a pathway to defend against viral infection. However, the necroptosis machinery might also function in endocrine disease even in the absence of infection. During evolution, viruses developed mechanisms to evade their host’s defence and the immune systems30,31. Upon the viral inhibition of caspase 8, RIPK1 and RIPK3 are no longer inhibited by the caspases’ proteolytic activity30,31. The failure of caspase 8 to cleave RIPK1, which can be a consequence of human mutations, results in autoimmunity32,33. In such situations and upon the genetic loss of caspase 8, RIPK3 oligomerizes34,35 through its RIP homotypic interaction motif (RHIM) domain to form a large amyloid-like platform36,37, which is referred to as the necrosome.

In addition to RIPK1 and RIPK3, there are only two other human encoded proteins that contain a similar RHIM domain (Fig. 1b). One such protein, Z-DNA-binding protein 1 (ZBP1; also known as DAI), recognizes intracellular oligonucleotides38,39,40,41,42,43, thereby merging another detection strategy to the necroptosis machinery as these oligonucleotides typically appear during viral infection. Along similar lines, the TIR domain-containing adapter-inducing interferon-β (TRIF) contains a RHIM domain and links the necroptosis machinery to bacterial host recognition44,45,46. In all of these cases, mixed lineage kinase domain-like (MLKL) represents the downstream effector of necroptosis5,47 following phosphorylation by the RIPK3 kinase domain48,49,50. It is unclear how pMLKL actually causes the loss of plasma membrane integrity, but it is clear that the endosomal sorting complexes required for the transport (ESCRT-III) complex15,51,52 antagonize necroptosis to a certain extent, most likely as a means of membrane repair. The necroptosis-driven response to single-stranded RNA viruses includes the host defence against influenza A viruses53 and SARS-CoV-2 (ref.54). Serum levels of RIPK3 have been demonstrated to be upregulated in patients with COVID-19 (ref.55). Therefore, necroptosis might also represent a mechanism underlying the virally induced destruction of pancreatic β-cells56.

Although the upstream modulators of ZBP1 and TRIF have been characterized, death receptor-mediated necroptosis is the modulator that has been best characterized. As mentioned earlier in this Perspective, the membrane-bound TNF receptor signalling complex becomes untethered upon the loss of post-translational modification motifs on RIPK1, such as polyubiquitin chains. Such chains can be assembled in a different way, for example, by K48 linkages that target proteins in proteasomal degradation. However, K63 ubiquitin linkages or linear linkages (also known as M1 linkages) on RIPK1 are assembled by different E3-ligase complexes. The cellular inhibitor of apoptosis protein 1 (cIAP1) and inhibitor of apoptosis protein 2 (cIAP2) are involved in RIPK1 K63 polyubiquitination57,58. Likewise, the linear ubiquitin chain assembly complex (LUBAC), which consists of the proteins SHARPIN, HOIP and HOIL1, generates linear polyubiquitin chains59,60,61. The polyubiquitin chains are disassembled by the deubiquitinases (DUBs) referred to as A20 (refs62,63) and CYLD20,64,65,66,67 in the case of K63 linkages and as OTULIN68,69,70 in the case of linear chains. It is this subtle equilibrium of post-translational modification that determines if the kinases IKKε and TBK1 are recruited into the complex and prevent cell death signalling either by apoptosis71 or by necroptosis19. In addition, the sensitivity to necroptosis is further regulated on different phosphorylation sites on RIPK1 (refs23,72,73) by the proteins MK2 (refs74,75) and TAK1 (ref.76).

Pyroptosis: gasdermin-mediated necrosis to amplify inflammasome action

Inflammasomes are intracellular supramolecular complexes, the proteolytic activity of which is mediated by caspase 1 and caspase 11 in mice (caspase 4 in humans)77,78. Three important cytosolic proteins contain a cleavage site for those caspases and are therefore activated by inflammasomes: pro-IL-1β and pro-IL-18 are cleaved by caspase 1, gasdermin D (GSDMD) can be cleaved by caspase 11 (refs79,80,81). However, the mature cytokines IL-1β and IL-18 do not contain a sorting motif and thereby cannot be actively secreted by exocytosis. Despite being a matter of scientific controversy, it is clear that pro-inflammatory cytokines can reach interstitial space through the activation of GSDMD following its proteolytic cleavage by caspase 11. A 28-fold single-ring pore forms from the N-terminal fragments, as demonstrated in detail for gasdermin A3 (ref.82), another member of the GSDM family, to execute necrotic cell death by pyroptosis (Fig. 1c). Importantly, GSDMD-deficient mice are protected from lipopolysaccharide-mediated shock. The role of pyroptosis in infectious diseases has been clearly established. However, in the past few years, it has become clear that gasdermins are controlled by caspase 8 (refs22,83), which was also demonstrated to function upstream of inflammasome activation84,85,86,87. Mechanistically, the death effector domain (DED) of caspase 8, at least in cell culture, was demonstrated to bind to ASC22 but confirming data in mice are lacking to this day.

Other members of the GSDM family might exert similar pore-forming functions. It has been noted that gasdermin E (GSDME) can be activated by caspase 3 during apoptosis88,89. Interestingly, GSDMD also contains a caspase 3 cleavage site90, which functions to inactivate the molecule and preclude pore formation by the GSDMD N-terminal fragment88,89,91. If the ESCRT-III complex inefficiently counteracts the formation of pores by actively releasing exosomes that contain GSDMD N-terminal fragments92, a plasma membrane rupture is triggered, thus defining the process of pyroptosis79,80,81. It will be interesting to see which other proteases might potentially activate members, other than GSDMD and GSDME, that do not carry a caspase cleavage site. In addition, some evidence suggests that caspase 8 might be involved in GSDMD cleavage independently of inflammasomes93,94,95. It will be interesting to unravel the non-inflammasome-mediated roles of gasdermins.

Ferroptosis: ancient iron-dependent necrosis by lipid peroxidation

Ferroptosis (Fig. 1d) is unlike apoptosis, necroptosis and pyroptosis in many ways. First, it is not induced by classic signalling, such as through a death receptor or a DNA sensor. Second, it is entirely unclear how the plasma membrane might rupture in ferroptosis. Finally, cell death by ferroptosis occurs in a non-cell-autonomous manner referred to as synchronized regulated necrosis. A model of cell death propagation, best studied in renal tubules96, is presented in Fig. 2. Besides kidney tubules, synchronized regulated necrosis has been reported in cell culture97,98 and zebrafish99. A calcium signal precedes membrane rupture minutes before the cells undergo necrosis98. However, it is beyond the scope of this Perspective to list the detailed considerations of ferroptosis execution and we refer the interested reader to excellent articles on this topic100,101; it should be mentioned that it remains unclear what initiates the spread of ferroptotic cell death102.

Fig. 2: Synchronized regulated necrosis.

In most cases, it is currently unclear how a necrotic zone of dead cells propagates during an event of sepsis or ischaemia. Based on time-lapse videos obtained from isolated perfused renal tubules that underwent ferroptosis, the concept of synchronized regulated necrosis emerged96. Although this phenomenon has not been observed in humans, necrotic tubules in the urine of patients and experimental intravital microscopy videos suggest that cell death occurs in a wave of death97,222. Given the connections between cells in a functional syncytium, such as a renal tubule, the adrenal gland or the myocardium, it is tempting to speculate that the intracellular redox capacity (NADPH concentration) diffuses through intercellular junctions. If the redox capacity decreases in a dying cell, an NADPH gradient forms, which leaves the closest neighbour at high risk of undergoing ferroptosis. At least from heart attacks and insults of acute kidney injury, it is now clear that the bulk of the necrotic area that occurs during myocardial infarction or tubular necrosis originates from cells that underwent ferroptosis. We speculate that similar mechanisms might occur in the adrenal gland during sepsis or during resuscitation in intensive care units and potentially in other endocrine organs. AA, arachidonic acid; DAMP, damage-associated molecular pattern; FA, fatty acid; GPX4; glutathione peroxidase 4; GSH, glutathione; GSR, glutathione-disulfide reductase; GSSG, glutathione disulfide; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; PL-OH, phospholipid alcohol; PL-OOH, phospholipid hydroperoxide; RTA, radical-trapping antioxidant.

Ferroptosis is a necrotic-type cell death resulting from the dysfunction of molecules that, under healthy conditions, prevent lipid peroxidation101. Such redox systems become proportionally more important relative to the number of Fenton reactions that need to be controlled in given cells. The sensitivity to ferroptosis therefore varies between cell types, but our current understanding is that hormone-producing cells and cancer cells are particularly sensitive to death by lipid peroxidation7.

The most redundant and best-studied system to suppress lipid peroxidation in mammals depends on glutathione peroxidase 4 (GPX4)103,104,105,106. GPX4 metabolizes glutathione (GSH) to decrease the intracellular H2O2 concentration. Sufficient GSH is critical for GPX4 function and is provided by GSH synthase or the mevalonate pathway that requires cysteine, imported into the cell as cystine (the oxidized dimer form of cysteine) through the Cyc-Glu antiporter system xc (ref.107).

In 2020, the protein apoptosis-inducing factor mitochondria associated 2 (AIFM2) was renamed as ferroptosis suppressor protein 1 (FSP1) by two groups that discovered the oxidoreductase activity of FSP1 to effectively suppress ferroptosis in a GSH-independent manner108,109. The recruitment of FSP1 to the plasma membrane via its myristylation binding motifs seems to be required for effective ferroptosis prevention108,109.

In addition, prominin 2 was identified as another negative regulator of ferroptosis110. This pentaspanin protein is known to be implicated in the regulation of lipid dynamics and was demonstrated to sort ferritin into multivesicular bodies, the outer membrane of which might fuse with the plasma membrane and thereby release ferritin-containing vesicles from the cell110. This iron export might desensitize cells against ferroptosis, but it is currently unclear how the microenvironment might be affected by these mechanisms. The microenvironmental changes are of particular interest in light of ferroptosis as an event of synchronized regulated necrosis (Fig. 2).

Haploid cell screens have helped to identify that acyl-coenzyme A synthetase long-chain isoform 4 (ACSL4) is critical to sensitize cells to RSL3-induced ferroptosis111,112,113. A genetic deficiency of ACSL4 in specific organs is considered to be a knockout for ferroptosis. For the endocrine focus of this Perspective, however, it is equally important to mention that the tissue-specific ablation of ACSL4 can be dispensable for normal steroidogenesis114.

In addition, P450 oxidoreductase, an endoplasmic reticulum (ER)-associated enzyme that carries disease-causing mutations in congenital adrenal hyperplasia and Antley–Bixler syndrome115, has been found to promote ferroptosis116,117. However, this function seems to be independent of its interaction with P450 enzymes required for steroidogenesis but is instead dependent on its function to generate H2O2. Along similar lines, CYB5R1, another ER-associated oxidoreductase, has been found to synergistically modulate ferroptosis sensitivity in cases of decreased P450 oxidoreductase activity117.

The induction of ferroptosis can be achieved in several different ways. The inhibition of system xc (by erastin) is referred to as a class 1 ferroptosis inducer (FIN)107. Class 2 FINs, such as RSL3, directly target the enzymatically active pocket of GPX4, whereas class 3 FINs (such as FIN56) induce GPX4 degradation118. For FINO2, which is also referred to as a class 4 FIN, the mechanism of action is less clear119. Several cancers, including adrenocortical carcinomas, might be particularly sensitive to the induction of ferroptosis10,106,120,121,122,123.

Interconnection between cell death pathways

During viral infection, necroptosis seems to be a backup cell death pathway for those virally infected cells that express caspase inhibitors48. Mechanistically, several viral proteins inhibit the proteolytic function of caspase 8, which therefore no longer functions to activate caspase 3, caspase 6, caspase 7 and apoptosis30. The same proteolytic activity of caspase 8 is required for the inactivation of RIPK1 (ref.20), which in turn becomes active upon the viral inhibition of caspase 8 to pursue necroptosis48. This function requires a heterodimer complex of caspase 8 with the long form of cellular FLICE-inhibitory protein35. Impressively, along similar lines, RIPK3-deficiency rescues the lethal phenotype of caspase 8-deficient mice34,35. Furthermore, caspase 8 might directly recruit ASC through its death effector domain22 and thereby regulate inflammasome activation and pyroptosis22,83. In addition, it is under debate whether caspase 8, in some circumstances, is capable of directly activating GSDMD93,94,95. At the level of gasdermins, another crosstalk between apoptosis and pyroptosis exists. Active caspase 3 proteolytically inhibits pyroptosis by cleavage of GSDMD at a different cleavage site89. It was further demonstrated that cellular FLICE-inhibitory protein directly inhibits caspase 8-mediated GSDMD cleavage and pyroptosis124. These examples substantiate the crosslinks between apoptosis, necroptosis and pyroptosis, most prominently regulated by caspase 8 (ref.125). The interconnection between cell death pathways was best demonstrated by mutations of RIPK1 that prevent caspase cleavage; such mutations result in autoinflammatory diseases32.

As a common downstream mechanism, the ESCRT-III complex prevents the loss of membrane integrity by releasing pMLKL51,52 or GSDMD N-terminal-containing microvesicles92 from the cell surface, thereby regulating both necroptosis and pyroptosis sensitivity.

In contrast to the complex apoptosis–necroptosis–pyroptosis system, ferroptosis (with respect to what has been demonstrated to date) does not appear to be mechanistically connected in any way. Given the importance of ferroptosis, this seems to be unexpected. Indeed, the only common features of all necrosis pathways, including ferroptosis, are the loss of redox capacity during very late stage cell death18, plasma membrane rupture, and the release of DAMPs and, as introduced here for the first time, particularly in hormone-producing cells, the damage-induced release of endocrine factors (DIRE).


The evolutionary conservation of more than one pathway of regulated necrosis can be explained by the differences in the immunogenicity of necroptosis, pyroptosis and ferroptosis. The requirement for delicately balancing immune responses to regulated cell death becomes clear given the two inevitable consequences of cellular necrosis (Box 2).

Apoptosis versus necrosis

Apoptosis represents the default pathway of cellular turnover in higher organisms126. It does not cause pro-inflammatory reactions and the dying cells expose phosphatidylserine on the cell surface to ensure the rapid removal by macrophages126. Whereas apoptosis does not drive an active inflammatory response, and in fact the engulfment of apoptotic cells results in the production of anti-inflammatory cytokines (Box 3), necrotic cell death results in a DAMP-driven immune response. Intracellular antigens or neo-antigens exposed on membranes of damaged organelles or simply on large enough structures, such as the cytoskeleton or protein-signalling complexes, might trigger naive cells of the adaptive immune system and even cause the generation of antibodies. In mouse models of systemic lupus erythematosus, the failure to remove necrotic debris is associated with the production of anti-nuclear antibodies and auto-antibodies against double-stranded DNA127,128,129. Such consequences of necrotic cell death apply to all pathways of regulated and even traumatic necrosis.


The release of IL-33 (ref.130), referred to by some authors as a ‘necroptotic DAMP’131, results in the local activation of ST-2 receptors such as on the surface of regulatory T cells132. Thus, IL-33 signalling might result in the prominent appearance of such cells in the microenvironment surrounding a cell course that died by necroptosis132. However, IL-33 might also regulate the cross-priming process in dendritic cells130, but further work is needed to conclude whether such processes are clearly pro-inflammatory. The additional release of CXCL1 from necroptotically dying cells133 might inhibit infiltrating neutrophils (as opposed to neutrophil recruitment during ferroptosis). If necroptosis is interpreted as a defence mechanism against apoptosis-inhibiting viruses, it conceptually makes sense that the inflammatory response is limited to the microenvironment. However, necroptosis in gut stem cells accompanied with the loss of the gastrointestinal barrier function, induced by the absence of the transcription factor SETDB1, was sufficient to drive severe inflammatory bowel disease134,135. Along similar lines, an MLKL-missense mutation results in lethal neonatal inflammation136.


In the case of caspase 1-activating inflammasomes, IL-1β and IL-18 (two long-lasting cytokines) are released after maturation upon pyroptosis in addition to DAMPs and DIRE137,138. This does not appear to be the case if only caspase 11 is activated, which leads to GSDMD cleavage81 but not to maturation of the cytokines. Caspase 1-driven pyroptosis has been best described for activated monocytes and it remains unclear if induction of pyroptosis in, for instance, epithelial or malignant cells results in a similar pro-inflammatory signature81,139,140,141. Therefore, with respect to the immunogenicity of pyroptosis, the distinction between pyroptosis mediated by caspase 1 and caspase 11 or pyroptosis mediated by caspase 11 alone is obvious. In contrast to all other regulated cell death pathways, caspase 1-driven pyroptosis includes IL-1β and IL-18 release to fight intracellular bacteria. Clinically, these cytokines are associated with an increase in body temperature (fever) based on cytokine signalling in the hypothalamus142.


The best-studied response to synchronized regulated necrosis mediated by ferroptosis is the infiltration of neutrophils. Within 2 hours following reperfusion of a cardiac transplant, massive infiltration of the tissue by neutrophils was demonstrated by intravital microscopy143. Similarly, synchronized regulated necrosis in the kidney tubules (Fig. 2) is associated with a marked neutrophil activation144,145. However, to the best of our knowledge, the inflammatory signature of neutrophils in classic endocrine organs undergoing ferroptosis has not been tested and the recruiting factors remain to be identified. Some reports investigated short-lived lipid peroxides but this approach, like all others, does not allow the identification of a specific signal that might be therapeutically targeted91,143. Other features of ferroptosis-induced necroinflammation (for example, dendritic cell priming and naive B cell priming) are subject to investigation and it will be interesting to work out the concise interconnection between ferroptosis and the immune system.

Pharmacological modulation

During the past decade, medicinal chemists have developed several inhibitors or tried to repurpose existing drugs to prevent regulated necrosis146,147. Generally, inhibitors of necroptosis are referred to as ‘necrostatins’ and inhibitors of ferroptosis are known as ‘ferrostatins’. However, to the best of our knowledge, the term ‘pyrostatins’ has not been used and inhibitors of apoptosis are generally referred to as ‘caspase inhibitors’. By contrast, inducers of regulated cell death, such as the apoptosis inducer venetoclax148, have been added to the clinical routine for the treatment of haematological cancers and their therapeutic profile is expected to expand. Many necroptosis, pyroptosis and FINs are being developed122,149. For the purpose of this Perspective and with respect to clinical applicability, in our opinion, the pharmacological modulation of necroptosis and ferroptosis represents the most promising novel therapeutic approach to prevent inflammatory cell loss in a variety of diseases, such as T1DM.

Necrostatins, such as the small molecule necrostatin 1 (ref.150), have boosted the research in regulated necrosis due to their high specificity to RIPK1 kinase inhibition151. It was demonstrated that the original compound of necrostatin 1, in addition to targeting RIPK1, has some inhibitory effect against ferroptosis105 that can be explained by the reducing activity of a thiohydantoin in the structure of necrostatin 1 (ref.147). This finding has caused confusion in the cell death field; however, with the development of more specific inhibitors of the RIPK1 kinase domain (that is, necrostatin 1s)151 and the development of RIPK1 kinase-dead knock-in mice152,153,154, this problem was resolved. Inhibitors of RIPK3 (ref.155) and MLKL5 also exist and it might be most efficient to inhibit necroptosis by simultaneously targeting multiple steps of the pathway156.

The inhibition of ferroptosis might be of paramount therapeutic interest as it was demonstrated within the past decade to be the fundamentally important necrotic cell death mechanism that drives myocardial infarction-induced cardiomyocyte necrosis143,157,158,159, (haemorrhagic) stroke160,161, acute kidney injury96,162,163,164,165 and liver failure104,105. In addition, it seems to account for a marked amount of the necrotic content transplanted upon solid organ transplantation2,143,166. Inhibitors of ferroptosis (ferrostatins) are readily available for preclinical research and it will be exciting to see their transfer to clinical trials146,167. Specific ferroptosis inhibitors, such as ferrostatin 1 (ref.107), 16-86 (a novel third-generation ferrostatin)96, liproxstatin 1 (ref.105) or UCAM-3203/3206 (ref.168), allowed the detection of the broad clinical importance of ferroptosis in cardiovascular diseases but hardly any endocrine disorders have been investigated with these novel inhibitors. By contrast, the four classes of FINs are widely used. Class 1 FINs (such as erastin) inhibit system xc (ref.169), whereas class 2 FINs (such as RSL3) directly target the active centre of GPX4 (ref.106). FIN56, the prototype class 3 FIN, functions by inducing the degradation of GPX4 (ref.118). Finally, the precise mechanism of FINO2 as a class 4 FIN has not been fully identified119. In addition, inhibitors of the FSP1 oxidoreductase108,109 or thioredoxin, such as ferroptocide149, offer even more options to drive cells into ferroptosis. It will be interesting to see cell lines of endocrine malignancies treated with FINs of all classes as a road to novel therapies.

The translational potential of an expanded understanding of regulated necrosis might not be limited to the inhibition of cell death and necroinflammation. By contrast, cancers, including adrenocortical carcinomas in particular, upregulate anti-ferroptosis proteins such as GPX4 (ref.10). This dependency provides a selective advantage to the tumour cells to more potently resist lipid peroxidation that originates, for example, from mitochondria in cells that consume high energy levels106,123. However, GPX4 expression, in the case of adrenocortical carcinomas, is so much higher than in normal tissue that a ferroptosis-inducing strategy might be considered. One such compound, imidazole ketone erastin, did not exhibit a strong adverse effect profile in preclinical testing in rodents122. As it is expected that more endogenous anti-ferroptosis mechanisms will be discovered, such as FSP1, more therapeutic options might emerge.

The induction of necrotic cell death does not necessarily need to be limited to ferroptosis induction. Necroptosis was demonstrated to improve the T cell cross-priming mediated by dendritic cells that process necroptotic debris3. Indeed, necroptosis seems to be a tightly regulated pro-inflammatory signalling pathway170 not only because of the release of DAMPs171. These fundamental concepts led to the model of necroinflammation2,172, which can be exploited to boost cancer immunotherapy171,173,174 in general and in endocrine tumours in particular.

Cell death in endocrine disorders

It is beyond the scope of this Perspective to list all the endocrine disorders that might be associated with regulated cell death. The listed disorders were chosen based on our opinion on the strength of the evidence on cell death as a causative factor. Supplementary Fig. 1 provides a subjective overview of the selected endocrine organs and cell death pathways that might be involved. Supplementary Table 1 summarizes some of the previously published literature on cell death in endocrine disorders and is interpreted in light of the current knowledge on regulated necrosis.

Cell death in diabetes mellitus

Several stages of classic T1DM are pathophysiologically driven by necrosis pathways (Box 4; Supplementary Fig. 2). A paper published in 2015 demonstrated that autoreactive T cells do not induce classic apoptosis or necroptosis in pancreatic β-cells but instead cause another pathway of necrosis9. These reports are in line with the results of scientific attempts to induce FAS ligand (CD95L and CD178) expression in murine β-cells175, which resulted in a rapid destruction caused by neutrophil infiltration176. Given the evidence of ferroptosis to induce neutrophil infiltration within no more than 2 hours following cardiac transplantation143, we consider ferroptosis a possible mechanism of β-cell death. However, the mechanisms of how T cells drive a cell into ferroptosis are unclear (Box 4; Supplementary Fig. 2). With respect to the complications of T1DM-driven atherosclerosis, the evidence is clearer. Given the evidence on the role of necroptosis and ferroptosis in myocardial infarction157, such redox systems also apply more specifically during cardiac remodelling and diabetic cardiomyopathy177, implying that a hydrogen sulfide-based therapeutic strategy could be used to mitigate myocardial cell death in diabetic cardiomyopathy177. Specific necroptosis-deficient mice (MLKL knockout and/or RIPK1 kinase-dead knock-in) should be used in the future to confirm the published results.

Pancreatic islet transplantation and ferroptosis

In 2018, we demonstrated that pancreatic islets undergo massive ferroptosis upon isolation from donors in standard media, whereas the addition of ferrostatins as small molecules increases the transplantable number of islet equivalents178,179. Therefore, islet transplantation would potentially no longer be limited by the number of donor islets, as the cell death of β-cells can potentially be completely prevented.

As depicted in Supplementary Fig. 2, the transplantation of necrotic debris might activate naive B cells that differentiate into memory B cells upon immunosuppression. Years after transplantation, these memory B cells might become re-activated by the necrotic clearance of viruses in the graft cells and cause steroid-resistant antibody-mediated rejection of the transplanted tissues2,180. Experimentally, ferroptosis-deficient ACSL4-knockout pancreatic β-cells should be used to confirm the role of ferroptosis in islet transplantation.

Adrenal insufficiency

Adrenal insufficiency can originate following a series of insults, such as haemorrhagic, ischaemic, infectious, surgical or metastatic destruction of the adrenal tissue181,182,183. Depending on the nature of the pathophysiology, ischaemic and haemorrhagic destruction can be caused by ferroptosis and necroptosis, whereas the loss of adrenal cells during viral defence might be a consequence of apoptosis or necroptosis. In the special case of acute bacterial infection, such as in Waterhouse–Friedrichsen syndrome, the fulminating shock might cause ischaemic destruction but it cannot be excluded that bacteria inside the adrenal gland induce a macrophage response, including pyroptotic cell death184. In this setting, bleeding in the adrenal tissue might lower the threshold for ferroptosis, given the presence of free iron from damaged erythrocytes. The adrenal tissue, therefore, exemplifies how several different cell death modes can affect the same organ7. More research is required to distinguish these modes and allocate clinical situations as indications for specific anti-cell-death treatments.

The importance of cell death in adrenal tissue additionally becomes obvious given the fact that Addison disease results from the loss of >90% of adrenal tissue before clinical presentation. Along similar lines, inflammation-related adrenal insufficiency might be triggered by necrotic cells and necroinflammation. Upon failure to remove necrotic cells through the molecule developmental endothelial locus 1, cell death, adrenal insufficiency and inflammation in adrenal tissue were exacerbated185. However, it remains unclear how the majority of adrenal cells die during the progression of adrenal insufficiency. Future research might consider the use of ferrostatins, necrostatins and specific genetic models (MLKL knockout or ACSL4-conditional deficiency in adrenal tissue) to confirm the preliminary findings.

Cell death in hypoparathyroidism

Autosomal dominant familial isolated hypoparathyroidism is an orphan disease that is caused by TUNEL-positive cell death186. Mechanistically, mutations result in a non-functional human preproparathyroid hormone that is trapped in the ER before the release process can start186. It remains unclear if the resulting ER stress triggers necrotic cell death, for example, by ferroptosis or necroptosis. Importantly, expression upon co-incubation with 4-phenylbutyric acid prevents the misfolding of preproparathyroid hormone and the death of the cell. Additionally, the secretion of the mutated hormone was shown to be restored. Other reports concluded that 4-phenylbutyric acid supplementation prevents ER stress and reduces levels of 4-hydroxy-trans-2-nonenal and lipid peroxidation187. However, ER stress has also been implicated as an originating factor of ferroptotic cell death188.

Disorders of the thyroid gland

Radioiodine therapy drives necrotic cell death in thyroid adenomas and Graves disease as well as in malignant tumours of the thyroid189. In clinical practice, 131-iodine therapy is associated with DIRE (in this case initial hyperthyroidism followed by thyroid failure) and can therefore be prevented by the administration of peroxidase inhibitors of the thioamide family, such as carbimazole. Interestingly, a known adverse effect of radioiodine therapy is irradiation-associated thyroiditis. Along similar lines, one report suggested that excessive iodine therapy promotes pyroptosis in Hashimoto thyroiditis190. In conclusion, radiation and radioiodine treatment of thyroid follicular epithelial cells can cause follicular cell necrosis and thereby drive necroinflammation and DIRE.

Primary thyrotoxicosis (associated with high free tetra-iodothyronine (T4) and low TSH) is a prototype complication caused by the release of DIRE, in this case T4. By contrast, tri-iodothyronine (T3) toxicosis clinically appears as a special condition but pathophysiologically also includes T3-DIRE release. Through similar mechanisms, thyrotoxicosis might occur secondary to an infarcted thyroid adenoma191 and simply any condition that causes thyroid cell necrosis.

Another thyroid disease with a high release of thyroid hormone DIRE is the painful subacute thyroiditis called De Quervain syndrome. This inflammatory thyroid disease with a potential viral aetiology background presents with clinical laboratory manifestations of local and systemic inflammation, including elevated levels of TNF192. In the early phase, there is a destruction of follicular epithelial cells with colloid extravasation and infiltration of follicles predominately by neutrophils forming micro-abscesses. A tri-phasic endocrine manifestation is characterized by initial thyroid hormone release inducing thyrotoxicosis, followed by thyroid destruction-induced hypothyroidism and eventually a return to normal conditions with euthyroidism. Cell death has been implicated in the pathophysiology of hypothyroidism192 but a detailed analysis of the specific mechanism is lacking.

Growth hormone deficiency

Isolated autosomal dominant growth hormone deficiency (IGHD) has been associated with increased cellular proliferation and apoptosis193. ER stress might be a driver of IGHD194, associated with complex patterns of caspase activation194 that might indicate crosstalk to the necroptosis pathway. Finally, it was demonstrated that GH inhibits p53 in colon carcinomas195, indicating that GH might regulate the ferroptosis sensitivity that might also play a role in pituitary cells. Clearly, more work on cell death, for example, through the use of ferrostatins and necrostatins, is needed to clarify which pathway most prominently causes IGHD.

Primary aldosteronism

Aldosterone was reported to induce cell death in aortic cells, a result that was interpreted as apoptosis at this time196. Somatic mutations in aldosterone-producing adenomas can induce cell death. In particular, higher percentages of dead cells were observed upon KCNJ5-G151R, G151E and L168R mutations under conditions tested with the incubation of cumate197 when compared with cells carrying the KCNJ5-T158A mutation. Interestingly, these observations were associated with the immunofluorescence detection of cleaved PARP, a downstream molecule that carries a caspase cleavage site and was therefore often interpreted as apoptosis. This nuclear staining for positive cleaved PARP in the nuclei of KCNJ5-G151E-transfected and L168R-transfected cells was significantly higher than in mock-transfected controls. These data indicate that apoptosis might be caused by aldosterone mutants, although it is unclear how the apoptotic pathway might be activated in such conditions.


Leydig cells are particularly sensitive to the induction of cell death by oxygen radicals and an important role for peroxiredoxin 2 has been discovered to prevent this form of cell death198. The sensitive cells in this study exhibited a markedly lower testosterone production, but experimentally it remains unclear if this effect is due to less cellular mass following cell loss198. In primordial germ cells, DNA repair is of particular importance. Fanconi anaemia is associated with hypogonadism and is caused by germline mutations in DNA repair pathways, such as p53-p21. Interestingly, a study published in 2014 indicated that hypogonadism in patients with Fanconi anaemia is not associated with apoptosis and it was indirectly concluded that a lesser rate of proliferation might cause this syndrome199. However, besides its well-defined functions in proliferation and cell cycle progression200, p53 is known to be involved in the ferroptosis pathway120,201. In addition, p53 is known to regulate the mevalonate pathway, an alternative cellular source of GSH202.

Haemochromatosis, iron overload states and endocrine dysfunction

Iron-catalysed necrosis (ferroptosis) was demonstrated to be a critical mediator of the most common cardiovascular events, including heart attacks143,157,158 and strokes150,160. In genetically predisposed patients, such as those with the C282Y mutation of the HFE gene linked to the HLA-A locus on chromosome 6p, the liver is the most affected organ203. Direct damage to pancreatic islets, most likely induced by ferroptosis, occurs frequently in up to 65% of symptomatic patients with haemochromatosis. Other complications include cardiac arrhythmias and congestive heart failure in approximately 15% of affected patients. Hypogonadism, caused by undefined cell death, can antedate other clinical features. Interestingly, the HFE gene has been associated with far more common hepatic conditions, such as non-alcoholic steatosis204, that also might involve ferroptosis205,206.

Cell death in endocrine malignancies

As is the case with the endocrine disorders described in the previous section, it is beyond the scope of this Perspective to list all the endocrine malignancies that might be associated with regulated cell death. Please refer to Supplementary Fig. 1 for a subjective overview of the selected endocrine organs and cell death pathways that might be involved.

Cell death in adrenocortical carcinoma

It has been recognized for decades that adrenocortical carcinomas exhibit high levels of TUNEL positivity207 (Box 1) and that mutations in the tumour suppressor p53 frequently occur208, although not in all populations in the same manner209. However, in 2019, we discovered the exquisite sensitivity of adrenocortical carcinomas to the induction of ferroptosis10, a necrotic-type cell death that explains both TUNEL positivity and regulation by p53. Interestingly, in contrast to GPX4, members of the glutathione peroxidase family were found amongst the most frequently mutated genes in adrenocortical carcinomas (encoding GPX3, GPX7 and GPX8)210,211. The same studies also found lipoxygenases, such as ALOX12, to be mutated, potentially as a tumour strategy to evade ferroptotic cell death. Along similar lines, thioredoxin reductases were overexpressed, potentially as a means to avoid lipid peroxidation210,211. Indeed, thioredoxin inhibition by a compound named ferroptocide was reported to drive cancer cells into ferroptosis149; however, this has not been investigated in adrenocortical carcinomas so far. In addition, other strategies that specifically target endocrine cancers using imidazole ketone erastin (a FIN) exist122 and will be developed further121. Currently, these efforts are at an experimental preclinical stage.

Cell death in phaeochromocytoma and paragangliomas

DNA methylation profiling in phaeochromocytoma and paraganglioma revealed GPX3 as a frequently mutated prognostic marker212. It is nevertheless unclear if and how GPX3 functions to regulate ferroptosis. However, the evidence for ferroptosis is weak compared with that for adrenocortical carcinomas. One early study demonstrated 7 of 29 (24%) phaeochromocytomas to be associated with the loss of heterozygosity on 17p, the locus associated with p53 (ref.213). More research is necessary regarding models of phaeochromocytoma, for example, 3D human tumour models that contain a necrotic core214, to understand the nature of this cell death. It is clear that phaeochromocytomas are hyper-vascularized tumours with a central necrotic zone that can even be detected radiologically, referred to as the ‘ring sign’215. With respect to the release of catecholamines from necrotic phaeochromocytomas, another example of DIRE release (Fig. 3), it was noted that myocardial necrosis can be associated with adrenaline release216. In extreme cases, pheochromocytoma DIRE might lead to severe and eventually lethal shock217,218. Likewise, it is worth mentioning that, as early as 1961, a case report pointed to a potentially mechanistic link between phaeochromocytoma and acute tubular necrosis219, the potential mechanism of which remained entirely unclear.

Fig. 3: DAMPs and DIRE and the consequences of cell death.

Regulated necrosis (necroptosis, ferroptosis and pyroptosis) and non-regulated necrosis, such as mechanical manipulation of tissue, results in the release of damage-associated molecular patterns (DAMPs) in non-endocrine cells (part a). By contrast, endocrine cells that die by necrosis are associated with the release of DAMPs and damage-induced release of endocrine factors (DIRE) (part b). Such factors include common hormones, such as cortisol, adrenaline, noradrenaline, thyroxin, tri-iodothyronine and aldosterone.

Ferroptosis and thyroid cancer

The targeting the pentose phosphate pathway in thyroid cancer cells was demonstrated to be associated with increased cell death dependent on the reactive oxygen species load, a typical feature of ferroptosis220. An association with ER stress has also been linked to ferroptosis188. Along similar lines, neutrophil gelatinase-associated lipocalin (NGAL), an iron scavenging NF-κB target protein, was identified to function as a survival factor for thyroid cancers221. These data led to the hypothesis that thyroid cancers evade ferroptosis to promote cancer survival. However, given the paucity of easy-to-assess biomarkers of ferroptosis, specific ferroptosis-inhibitors and GPX4-deficient genetic models will enable the confirmation of the role of ferroptosis in thyroid cancer.


We are only just beginning to understand the role of regulated necrosis in endocrine disorders. As endocrinologists, we are still struggling to understand many of the fundamental unique features of the endocrine systems and a number of open questions and obstacles remain.

First, the endocrine system is characterized by an extraordinary ability to respond to internal and external stimuli with impressive adaptive cellular and structural changes. Second, benign endocrine lesions and nodules are more frequent than in any other tissue, while malignant tumour formation in endocrine glands is a rare event. Third, the vulnerability of some endocrine tissues to rapid cellular degeneration, such as the adrenal cortex during sepsis and inflammation, is hardly understood but clearly associated with cellular turnover. Fourth, the susceptibility of some endocrine tissues to autoimmune diseases, such as T1DM or Hashimoto disease, cannot be explained in detail, especially not with respect to the other glands that are rarely affected by immune destruction. Fifth, the role of regulated cell death has hardly been investigated in some of the more common endocrine disorders, such as all forms of diabetes mellitus, obesity, hyperlipidaemia, Graves disease and primary hyperaldosteronism. The investigation of regulated necrosis in such diseases will probably further expand the future options for clinical applications. Finally, we cannot currently sufficiently explain the relatively easy (auto) transplantability of some endocrine organs, such as parathyroids or islets, whereas other endocrine tissues, such as testes or adrenal tissue, completely lose their functions in a foreign organ environment. We believe that a molecular understanding of regulated cell death and necroinflammation will help to answer these open questions and enable the development of novel therapeutic strategies from this research area.


  1. 1.

    Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 25, 486–541 (2018).

    PubMed  PubMed Central  Google Scholar 

  2. 2.

    Sarhan, M., Land, W. G., Tonnus, W., Hugo, C. P. & Linkermann, A. Origin and Consequences of Necroinflammation. Physiol. Rev. 98, 727–780 (2018).

    CAS  PubMed  Google Scholar 

  3. 3.

    Yatim, N. et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8+ T cells. Science 350, 328–334 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Linkermann, A. et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 110, 12024–12029 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 (2012).

    CAS  PubMed  Google Scholar 

  6. 6.

    Vanden Berghe, T. et al. Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock. Am. J. Respir. Crit. Care Med. 189, 282–291 (2014).

    CAS  PubMed  Google Scholar 

  7. 7.

    Tonnus, W. et al. The clinical relevance of necroinflammation-highlighting the importance of acute kidney injury and the adrenal glands. Cell Death Differ. 26, 68–82 (2019).

    CAS  PubMed  Google Scholar 

  8. 8.

    Tonnus, W. & Linkermann, A. “Death is my Heir” – ferroptosis connects cancer pharmacogenomics and ischemia-reperfusion injury. Cell Chem. Biol. 23, 202–203 (2016).

    CAS  PubMed  Google Scholar 

  9. 9.

    Zhao, Y. et al. Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes. Diabetologia 58, 140–148 (2015).

    CAS  PubMed  Google Scholar 

  10. 10.

    Belavgeni, A. et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proc. Natl Acad. Sci. USA 116, 22269–22274 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Nagata, S. Apoptosis and autoimmune diseases. Ann. NY Acad. Sci. 1209, 10–16 (2010).

    CAS  PubMed  Google Scholar 

  12. 12.

    Segawa, K. & Nagata, S. An apoptotic ‘eat me’ signal: phosphatidylserine exposure. Trends Cell Biol. 25, 639–650 (2015).

    CAS  PubMed  Google Scholar 

  13. 13.

    Hanayama, R. et al. Identification of a factor that links apoptotic cells to phagocytes. Nature 417, 182–187 (2002).

    CAS  PubMed  Google Scholar 

  14. 14.

    Suzuki, J., Denning, D. P., Imanishi, E., Horvitz, H. R. & Nagata, S. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science 341, 403–406 (2013).

    CAS  PubMed  Google Scholar 

  15. 15.

    Zargarian, S. et al. Phosphatidylserine externalization, “necroptotic bodies” release, and phagocytosis during necroptosis. PLoS Biol. 15, e2002711 (2017).

    PubMed  PubMed Central  Google Scholar 

  16. 16.

    Krammer, P. H., Arnold, R. & Lavrik, I. N. Life and death in peripheral T cells. Nat. Rev. Immunol. 7, 532–542 (2007).

    CAS  PubMed  Google Scholar 

  17. 17.

    Ofengeim, D. & Yuan, J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat. Rev. Mol. Cell Biol. 14, 727–736 (2013).

    CAS  PubMed  Google Scholar 

  18. 18.

    Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. & Vandenabeele, P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 15, 135–147 (2014).

    CAS  PubMed  Google Scholar 

  19. 19.

    Lafont, E. et al. TBK1 and IKKepsilon prevent TNF-induced cell death by RIPK1 phosphorylation. Nat. Cell Biol. 20, 1389–1399 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Newton, K. et al. Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. Nature 574, 428–431 (2019).

    CAS  PubMed  Google Scholar 

  21. 21.

    Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Litwack, G. & Alnemri, E. S. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl Acad. Sci. USA 93, 14486–14491 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Newton, K. et al. Activity of caspase-8 determines plasticity between cell death pathways. Nature 575, 679–682 (2019).

    CAS  PubMed  Google Scholar 

  23. 23.

    Dondelinger, Y., Darding, M., Bertrand, M. J. & Walczak, H. Poly-ubiquitination in TNFR1-mediated necroptosis. Cell Mol. Life Sci. 73, 2165–2176 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Peltzer, N., Darding, M. & Walczak, H. Holding RIPK1 on the ubiquitin leash in TNFR1 signaling. Trends Cell Biol. 26, 445–461 (2016).

    CAS  PubMed  Google Scholar 

  25. 25.

    Walczak, H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol. Rev. 244, 9–28 (2011).

    CAS  PubMed  Google Scholar 

  26. 26.

    Czabotar, P. E., Lessene, G., Strasser, A. & Adams, J. M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49–63 (2014).

    CAS  PubMed  Google Scholar 

  27. 27.

    Acehan, D. et al. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell 9, 423–432 (2002).

    CAS  PubMed  Google Scholar 

  28. 28.

    Pop, C., Timmer, J., Sperandio, S. & Salvesen, G. S. The apoptosome activates caspase-9 by dimerization. Mol. Cell 22, 269–275 (2006).

    CAS  PubMed  Google Scholar 

  29. 29.

    Zou, H., Li, Y., Liu, X. & Wang, X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274, 11549–11556 (1999).

    CAS  PubMed  Google Scholar 

  30. 30.

    Kaiser, W. J., Upton, J. W. & Mocarski, E. S. Viral modulation of programmed necrosis. Curr. Opin. Virol. 3, 296–306 (2013).

    CAS  PubMed  Google Scholar 

  31. 31.

    Mocarski, E. S., Upton, J. W. & Kaiser, W. J. Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. Nat. Rev. Immunol. 12, 79–88 (2011).

    PubMed  PubMed Central  Google Scholar 

  32. 32.

    Lalaoui, N. et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature 577, 103–108 (2020).

    CAS  PubMed  Google Scholar 

  33. 33.

    Tao, P. et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1. Nature 577, 109–114 (2020).

    CAS  PubMed  Google Scholar 

  34. 34.

    Kaiser, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368–372 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Oberst, A. et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471, 363–367 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Li, J. et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150, 339–350 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Mompean, M. et al. The structure of the necrosome RIPK1-RIPK3 Core, a human hetero-amyloid signaling complex. Cell 173, 1244–1253.e10 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Kaiser, W. J., Upton, J. W. & Mocarski, E. S. Receptor-interacting protein homotypic interaction motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN regulatory factors. J. Immunol. 181, 6427–6434 (2008).

    CAS  PubMed  Google Scholar 

  39. 39.

    Rebsamen, M. et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep. 10, 916–922 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Upton, J. W., Kaiser, W. J. & Mocarski, E. S. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11, 290–297 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Kuriakose, T. et al. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci. Immunol. 1, aag2045 (2016).

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Lin, J. et al. RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation. Nature 540, 124–128 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Newton, K. et al. RIPK1 inhibits ZBP1-driven necroptosis during development. Nature 540, 129–133 (2016).

    CAS  PubMed  Google Scholar 

  44. 44.

    Kaiser, W. J. & Offermann, M. K. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J. Immunol. 174, 4942–4952 (2005).

    CAS  PubMed  Google Scholar 

  45. 45.

    Kaiser, W. J. et al. Toll-like Receptor 3-mediated necrosis via TRIF, RIP3 and MLKL. J. Biol. Chem. 288, 31268–31279 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Dillon, C. P. et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 157, 1189–1202 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Zhao, J. et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl Acad. Sci. USA 109, 5322–5327 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Cho, Y. S. et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112–1123 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. 49.

    He, S. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100–1111 (2009).

    CAS  PubMed  Google Scholar 

  50. 50.

    Zhang, D. W. et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325, 332–336 (2009).

    CAS  PubMed  Google Scholar 

  51. 51.

    Gong, Y.-N. et al. ESCRT-III Acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell 169, 286–300.e16 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Yoon, S., Kovalenko, A., Bogdanov, K. & Wallach, D. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity 47, 51–65.e7 (2017).

    CAS  PubMed  Google Scholar 

  53. 53.

    Nogusa, S. et al. RIPK3 activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis to protect against influenza a virus. Cell Host Microbe 20, 13–24 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Karki, R. et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149–168.e17 (2021).

    CAS  PubMed  Google Scholar 

  55. 55.

    Nakamura, H. et al. Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19. Crit. Care 24, 484 (2020).

    PubMed  PubMed Central  Google Scholar 

  56. 56.

    Hollstein, T. et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat. Metab. 2, 1021–1024 (2020).

    CAS  PubMed  Google Scholar 

  57. 57.

    Vanlangenakker, N. et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 18, 656–665 (2011).

    CAS  PubMed  Google Scholar 

  58. 58.

    Feoktistova, M. et al. cIAPs block ripoptosome formation, a RIP1/Caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 43, 449–463 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Peltzer, N. et al. LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. Nature 557, 112–117 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Ikeda, F. et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 471, 637–641 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Haas, T. L. et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36, 831–844 (2009).

    CAS  PubMed  Google Scholar 

  62. 62.

    Onizawa, M. et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat. Immunol. 16, 618–627 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694–699 (2004).

    CAS  PubMed  Google Scholar 

  64. 64.

    Hrdinka, M. et al. CYLD limits Lys63- and Met1-linked ubiquitin at receptor complexes to regulate innate immune signaling. Cell Rep. 14, 2846–2858 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Moquin, D. M., McQuade, T. & Chan, F. K. CYLD deubiquitinates RIP1 in the TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PloS ONE 8, e76841 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793–796 (2003).

    CAS  PubMed  Google Scholar 

  67. 67.

    Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801–805 (2003).

    CAS  PubMed  Google Scholar 

  68. 68.

    Heger, K. et al. OTULIN limits cell death and inflammation by deubiquitinating LUBAC. Nature 559, 120–124 (2018).

    CAS  PubMed  Google Scholar 

  69. 69.

    Damgaard, R. B. et al. The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell 166, 1215–1230 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Keusekotten, K. et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 153, 1312–1326 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Xu, D. et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell 174, 1477–1491.e19 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Dondelinger, Y. et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 20, 1381–1392 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Dondelinger, Y. et al. NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death TNF signaling. Mol. Cell 60, 63–76 (2015).

    CAS  PubMed  Google Scholar 

  74. 74.

    Annibaldi, A. et al. Ubiquitin-mediated regulation of RIPK1 kinase activity Independent of IKK and MK2. Mol. Cell 69, 566–580.e5 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  75. 75.

    Jaco, I. et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66, 698–710.e5 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Mihaly, S. R., Ninomiya-Tsuji, J. & Morioka, S. TAK1 control of cell death. Cell Death Differ. 21, 1667–1676 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  77. 77.

    de Vasconcelos, N. M., Van, O. N. & Lamkanfi, M. Inflammasomes as polyvalent cell death platforms. Cell Mol. Life Sci. 73, 2335–2347 (2016).

    PubMed  Google Scholar 

  78. 78.

    Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407–420 (2016).

    CAS  PubMed  Google Scholar 

  79. 79.

    Ding, J. et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111–116 (2016).

    CAS  PubMed  Google Scholar 

  80. 80.

    Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signaling. Nature 526, 666–671 (2015).

    CAS  PubMed  Google Scholar 

  81. 81.

    Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).

    CAS  PubMed  Google Scholar 

  82. 82.

    Ruan, J., Xia, S., Liu, X., Lieberman, J. & Wu, H. Cryo-EM structure of the gasdermin A3 membrane pore. Nature 557, 62–67 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  83. 83.

    Fritsch, M. et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature 575, 683–687 (2019).

    CAS  PubMed  Google Scholar 

  84. 84.

    Kang, T. B., Yang, S. H., Toth, B., Kovalenko, A. & Wallach, D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 38, 27–40 (2013).

    CAS  PubMed  Google Scholar 

  85. 85.

    Lawlor, K. E. et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat. Commun. 6, 6282 (2015).

    CAS  PubMed  Google Scholar 

  86. 86.

    Philip, N. H. et al. Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-kappaB and MAPK signaling. Proc. Natl Acad. Sci. USA 111, 7385–7390 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Vince, J. E. et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 36, 215–227 (2012).

    CAS  PubMed  Google Scholar 

  88. 88.

    Rogers, C. et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat. Commun. 10, 1689 (2019).

    PubMed  PubMed Central  Google Scholar 

  89. 89.

    Wang, Y. et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a Gasdermin. Nature 547, 99–103 (2017).

    CAS  PubMed  Google Scholar 

  90. 90.

    Taabazuing, C. Y., Okondo, M. C. & Bachovchin, D. A. Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages. Cell Chem. Biol. 24, 507–514.e4 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  91. 91.

    Tonnus, W. et al. The pathological features of regulated necrosis. J. Pathol. 247, 697–707 (2019).

    CAS  PubMed  Google Scholar 

  92. 92.

    Ruhl, S. et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science 362, 956–960 (2018).

    PubMed  Google Scholar 

  93. 93.

    Mandal, P. et al. Caspase-8 collaborates with caspase-11 to drive tissue damage and execution of endotoxic shock. Immunity 49, 42–55.e6 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  94. 94.

    Orning, P. et al. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science 362, 1064–1069 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  95. 95.

    Sarhan, J. et al. Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection. Proc. Natl Acad. Sci. USA 115, E10888–E10897 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Linkermann, A. et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl Acad. Sci. USA 111, 16836–16841 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  97. 97.

    Kim, S. E. et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat. Nanotechnol. 11, 977–985 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  98. 98.

    Riegman, M. et al. Ferroptosis occurs through an osmotic mechanism and propagates independently of cell rupture. Nat. Cell Biol. 22, 1042–1048 (2020).

    PubMed  PubMed Central  Google Scholar 

  99. 99.

    Katikaneni, A. et al. Lipid peroxidation regulates long-range wound detection through 5-lipoxygenase in zebrafish. Nat. Cell Biol. 22, 1049–1055 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  100. 100.

    Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273–285 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  101. 101.

    Conrad, M. & Pratt, D. A. The chemical basis of ferroptosis. Nat. Chem. Biol. 15, 1137–1147 (2019).

    CAS  PubMed  Google Scholar 

  102. 102.

    Davidson, A. J. & Wood, W. Igniting the spread of ferroptotic cell death. Nat. Cell Biol. 22, 1027–1029 (2020).

    CAS  PubMed  Google Scholar 

  103. 103.

    Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237–248 (2008).

    CAS  PubMed  Google Scholar 

  104. 104.

    Yoo, S. E. et al. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic. Biol. Med. 52, 1820–1827 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  105. 105.

    Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).

    CAS  PubMed  Google Scholar 

  106. 106.

    Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  107. 107.

    Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  108. 108.

    Bersuker, K. et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688–692 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  109. 109.

    Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693–698 (2019).

    CAS  PubMed  Google Scholar 

  110. 110.

    Brown, C. W. et al. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev. Cell 51, 575–586 (2019).

    CAS  PubMed  Google Scholar 

  111. 111.

    Dixon, S. J. et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem. Biol. 10, 1604–1609 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  112. 112.

    Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91–98 (2017).

    CAS  PubMed  Google Scholar 

  113. 113.

    Kagan, V. E. et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017).

    CAS  PubMed  Google Scholar 

  114. 114.

    Wang, W. et al. Tissue-specific ablation of ACSL4 results in disturbed steroidogenesis. Endocrinology 160, 2517–2528 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  115. 115.

    Arlt, W. et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363, 2128–2135 (2004).

    CAS  PubMed  Google Scholar 

  116. 116.

    Soula, M. et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat. Chem. Biol. 16, 1351–1360 (2020).

    CAS  PubMed  Google Scholar 

  117. 117.

    Yan, B. et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol. Cell 81, 355–369.e10 (2021).

    CAS  PubMed  Google Scholar 

  118. 118.

    Shimada, K. et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12, 497–503 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  119. 119.

    Gaschler, M. M. et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol. 14, 507–515 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  120. 120.

    Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  121. 121.

    Yi, J., Minikes, A. M. & Jiang, X. Aiming at cancer in vivo: ferroptosis-inducer delivered by nanoparticles. Cell Chem. Biol. 26, 621–622 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  122. 122.

    Zhang, Y. et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem. Biol. 26, 623–633.e9 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  123. 123.

    Zou, Y. et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat. Commun. 10, 1617 (2019).

    PubMed  PubMed Central  Google Scholar 

  124. 124.

    Muendlein, H. I. et al. cFLIPL protects macrophages from LPS-induced pyroptosis via inhibition of complex II formation. Science 367, 1379–1384 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  125. 125.

    Malireddi, R. K. S. et al. Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease. J. Exp. Med. 217, jem.20191644 (2020).

    Google Scholar 

  126. 126.

    Nagata, S. Apoptosis and clearance of apoptotic cells. Annu. Rev. Immunol. 36, 489–517 (2018).

    CAS  PubMed  Google Scholar 

  127. 127.

    Green, D. R., Oguin, T. H. & Martinez, J. The clearance of dying cells: table for two. Cell Death. Differ. 23, 915–926 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  128. 128.

    Martinez, J. et al. Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat. Cell Biol. 17, 893–906 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  129. 129.

    Martinez, J. et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature 533, 115–119 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  130. 130.

    Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581–18586 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  131. 131.

    Rickard, J. A. et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157, 1175–1188 (2014).

    CAS  PubMed  Google Scholar 

  132. 132.

    Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  133. 133.

    Zhu, K. et al. Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis. 9, 500 (2018).

    PubMed  PubMed Central  Google Scholar 

  134. 134.

    Južnić, L. et al. SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation. Gut 70, 485–498 (2021).

    PubMed  Google Scholar 

  135. 135.

    Wang, R. et al. Gut stem cell necroptosis by genome instability triggers bowel inflammation. Nature 580, 386–390 (2020).

    CAS  PubMed  Google Scholar 

  136. 136.

    Hildebrand, J. M. et al. A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. Nat. Commun. 11, 3150 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  137. 137.

    Brough, D. & Rothwell, N. J. Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J. Cell Sci. 120, 772–781 (2007).

    CAS  PubMed  Google Scholar 

  138. 138.

    Bergsbaken, T., Fink, S. L., den Hartigh, A. B., Loomis, W. P. & Cookson, B. T. Coordinated host responses during pyroptosis: caspase-1-dependent lysosome exocytosis and inflammatory cytokine maturation. J. Immunol. 187, 2748–2754 (2011).

    CAS  PubMed  Google Scholar 

  139. 139.

    Vanden Berghe, T. et al. An inactivating caspase-11 passenger mutation muddles sepsis research. Am. J. Respir. Crit. Care Med. 188, 120–121 (2013).

    PubMed  Google Scholar 

  140. 140.

    Case, C. L. et al. Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to Legionella pneumophila. Proc. Natl Acad. Sci. USA 110, 1851–1856 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  141. 141.

    Broz, P. et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490, 288–291 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  142. 142.

    Mier, J. W. et al. Dissimilarities between purified human interleukin-1 and recombinant human interleukin-2 in the induction of fever, brain prostaglandin, and acute-phase protein synthesis. J. Biol. Response Mod. 4, 35–45 (1985).

    CAS  PubMed  Google Scholar 

  143. 143.

    Li, W. et al. Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. J. Clin. Invest. 129, 2293–2304 (2019).

    PubMed  PubMed Central  Google Scholar 

  144. 144.

    Allam, R. et al. Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J. Am. Soc. Nephrol. 23, 1375–1388 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  145. 145.

    Nakazawa, D. et al. Histones and neutrophil extracellular traps enhance tubular necrosis and remote organ injury in ischemic AKI. J. Am. Soc. Nephrol. 28, 1753–1768 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  146. 146.

    Degterev, A. & Linkermann, A. Generation of small molecules to interfere with regulated necrosis. Cell Mol. Life Sci. 73, 2251–2267 (2016).

    CAS  PubMed  Google Scholar 

  147. 147.

    von Massenhausen, A. et al. Phenytoin inhibits necroptosis. Cell Death Dis. 9, 359 (2018).

    Google Scholar 

  148. 148.

    Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).

    CAS  PubMed  Google Scholar 

  149. 149.

    Llabani, E. et al. Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis. Nat. Chem. 11, 521–532 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  150. 150.

    Degterev, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112–119 (2005).

    CAS  PubMed  Google Scholar 

  151. 151.

    Degterev, A., Maki, J. L. & Yuan, J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ. 20, 366 (2013).

    CAS  PubMed  Google Scholar 

  152. 152.

    Dannappel, M. et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513, 90–94 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  153. 153.

    Kaiser, W. J. et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc. Natl Acad. Sci. USA 111, 7753–7758 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  154. 154.

    Takahashi, N. et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513, 95–99 (2014).

    CAS  PubMed  Google Scholar 

  155. 155.

    Mandal, P. et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol. Cell 56, 481–495 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  156. 156.

    Pierotti, C. L. et al. Potent inhibition of Necroptosis by simultaneously targeting multiple effectors of the pathway. ACS Chem. Biol. 15, 2702–2713 (2020).

    CAS  PubMed  Google Scholar 

  157. 157.

    Del Re, D. P., Amgalan, D., Linkermann, A., Liu, Q. & Kitsis, R. N. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol. Rev. 99, 1765–1817 (2019).

    PubMed  PubMed Central  Google Scholar 

  158. 158.

    Fang, X. et al. Ferroptosis as a target for protection against cardiomyopathy. Proc. Natl Acad. Sci. USA 116, 2672–2680 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  159. 159.

    Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298–308 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  160. 160.

    Alim, I. et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. Cell 177, 1262–1279.e25 (2019).

    CAS  PubMed  Google Scholar 

  161. 161.

    Kenny, E. M. et al. Ferroptosis contributes to neuronal death and functional outcome after traumatic brain injury. Crit. Care Med. 47, 410–418 (2019).

    PubMed  PubMed Central  Google Scholar 

  162. 162.

    Adedoyin, O. et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am. J. Physiol. Ren. Physiol. 314, F702–F714 (2018).

    CAS  Google Scholar 

  163. 163.

    Deng, F., Sharma, I., Dai, Y., Yang, M. & Kanwar, Y. S. Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule. J. Clin. Invest. 129, 5033–5049 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  164. 164.

    Martin-Sanchez, D. et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J. Am. Soc. Nephrol. 28, 218–229 (2017).

    CAS  PubMed  Google Scholar 

  165. 165.

    Stoppe, C. et al. The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery. Sci. Transl Med. 10, eaan4886 (2018).

    PubMed  Google Scholar 

  166. 166.

    Schumann-Bischoff, A. et al. Distinct morphological features of acute tubular injury in renal allografts correlate with clinical outcome. Am. J. Physiol. Ren. Physiol. 315, F701–F710 (2018).

    CAS  Google Scholar 

  167. 167.

    Skouta, R. et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136, 4551–4556 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  168. 168.

    Devisscher, L. et al. Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy. J. Med. Chem. 61, 10126–10140 (2018).

    CAS  PubMed  Google Scholar 

  169. 169.

    Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864–868 (2007).

    PubMed  PubMed Central  Google Scholar 

  170. 170.

    Yatim, N., Cullen, S. & Albert, M. L. Dying cells actively regulate adaptive immune responses. Nat. Rev. Immunol. 17, 262–275 (2017).

    CAS  PubMed  Google Scholar 

  171. 171.

    Orozco, S. L. et al. RIPK3 activation leads to cytokine synthesis that continues after loss of cell membrane integrity. Cell Rep. 28, 2275–2287.e5 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  172. 172.

    Blander, J. M. Regulation of the cell biology of antigen cross-presentation. Annu. Rev. Immunol. 36, 717–753 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  173. 173.

    Snyder, A. G. et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci. Immunol. 4, eaaw2004 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  174. 174.

    Van Hoecke, L. et al. Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. Nat. Commun. 9, 3417 (2018).

    PubMed  PubMed Central  Google Scholar 

  175. 175.

    Chervonsky, A. V. et al. The role of Fas in autoimmune diabetes. Cell 89, 17–24 (1997).

    CAS  PubMed  Google Scholar 

  176. 176.

    Kang, S. M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3, 738–743 (1997).

    CAS  PubMed  Google Scholar 

  177. 177.

    Kar, S., Kambis, T. N. & Mishra, P. K. Hydrogen sulfide-mediated regulation of cell death signaling ameliorates adverse cardiac remodeling and diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 316, H1237–H1252 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  178. 178.

    Bruni, A., Bornstein, S., Linkermann, A. & Shapiro, A. M. J. Regulated cell death seen through the lens of islet transplantation. Cell Transplant. 27, 890–901 (2018).

    PubMed  PubMed Central  Google Scholar 

  179. 179.

    Bruni, A. et al. Ferroptosis-inducing agents compromise in vitro human islet viability and function. Cell Death Dis. 9, 595 (2018).

    PubMed  PubMed Central  Google Scholar 

  180. 180.

    Land, W. G., Agostinis, P., Gasser, S., Garg, A. D. & Linkermann, A. Transplantation and damage-associated molecular patterns (DAMPs). Am. J. Transplant. 16, 3338–3361 (2016).

    CAS  PubMed  Google Scholar 

  181. 181.

    Bornstein, S. R. Predisposing factors for adrenal insufficiency. N. Engl. J. Med. 360, 2328–2339 (2009).

    CAS  PubMed  Google Scholar 

  182. 182.

    Husebye, E. S., Pearce, S. H., Krone, N. P. & Kämpe, O. Adrenal insufficiency. Lancet 397, 613–629 (2021).

    CAS  PubMed  Google Scholar 

  183. 183.

    Merke, D. P. et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N. Engl. J. Med. 343, 1362–1368 (2000).

    CAS  PubMed  Google Scholar 

  184. 184.

    Hata, Y., Chiba, T., Ohtani, M., Ishizawa, S. & Nishida, N. An autopsy case of pneumococcal Waterhouse-Friderichsen syndrome with possible functional asplenia/hyposplenia. Int. J. Clin. Exp. Pathol. 8, 7518–7525 (2015).

    PubMed  PubMed Central  Google Scholar 

  185. 185.

    Kanczkowski, W. et al. Role of the endothelial-derived endogenous anti-inflammatory factor Del-1 in inflammation-mediated adrenal gland dysfunction. Endocrinology 154, 1181–1189 (2013).

    CAS  PubMed  Google Scholar 

  186. 186.

    Datta, R., Waheed, A., Shah, G. N. & Sly, W. S. Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc. Natl Acad. Sci. USA 104, 19989–19994 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  187. 187.

    Vladykovskaya, E. et al. Lipid peroxidation product 4-hydroxy-trans-2-nonenal causes endothelial activation by inducing endoplasmic reticulum stress. J. Biol. Chem. 287, 11398–11409 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  188. 188.

    Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523 (2014).

    PubMed  PubMed Central  Google Scholar 

  189. 189.

    Marx, K. et al. Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis? Nucl. Med. Commun. 27, 353–358 (2006).

    PubMed  Google Scholar 

  190. 190.

    Liu, J. et al. Excessive iodine promotes pyroptosis of thyroid follicular epithelial cells in Hashimoto’s thyroiditis through the ROS-NF-kappaB-NLRP3 pathway. Front. Endocrinol. 10, 778 (2019).

    CAS  Google Scholar 

  191. 191.

    Kodama, T. et al. Transient thyrotoxicosis associated with infarction of a large thyroid adenoma. Endocrinol. Jpn 34, 779–784 (1987).

    CAS  PubMed  Google Scholar 

  192. 192.

    Li, H. et al. TNF-alpha is upregulated in subacute thyroiditis and stimulates expression of miR-155-5p in thyroid follicle cells. Discov. Med. 26, 67–77 (2018).

    PubMed  Google Scholar 

  193. 193.

    Salemi, S. et al. Isolated autosomal dominant growth hormone deficiency: stimulating mutant GH-1 gene expression drives GH-1 splice-site selection, cell proliferation, and apoptosis. Endocrinology 148, 45–53 (2007).

    CAS  PubMed  Google Scholar 

  194. 194.

    Ariyasu, D., Yoshida, H., Yamada, M. & Hasegawa, Y. Endoplasmic reticulum stress and apoptosis contribute to the pathogenesis of dominantly inherited isolated GH deficiency due to GH1 gene splice site mutations. Endocrinology 154, 3228–3239 (2013).

    CAS  PubMed  Google Scholar 

  195. 195.

    Chesnokova, V. et al. Growth hormone is permissive for neoplastic colon growth. Proc. Natl Acad. Sci. USA 113, E3250–E3259 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  196. 196.

    Yan, Y. et al. Aortic cell apoptosis in rat primary aldosteronism model. J. Huazhong Univ. Sci. Technolog. Med. Sci. 30, 385–390 (2010).

    PubMed  Google Scholar 

  197. 197.

    Yang, Y. et al. Primary aldosteronism: KCNJ5 mutations and adrenocortical cell growth. Hypertension 74, 809–816 (2019).

    CAS  PubMed  Google Scholar 

  198. 198.

    Duan, T. et al. Role of peroxiredoxin 2 in H2O2induced oxidative stress of primary Leydig cells. Mol. Med. Rep. 13, 4807–4813 (2016).

    CAS  PubMed  Google Scholar 

  199. 199.

    Luo, Y. et al. Hypersensitivity of primordial germ cells to compromised replication-associated DNA repair involves ATM-p53-p21 signaling. PLoS Genet. 10, e1004471 (2014).

    PubMed  PubMed Central  Google Scholar 

  200. 200.

    Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  201. 201.

    Tarangelo, A. et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep. 22, 569–575 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  202. 202.

    Moon, S. H. et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell 176, 564–580.e19 (2019).

    CAS  PubMed  Google Scholar 

  203. 203.

    Brissot, P. et al. Haemochromatosis. Nat. Rev. Dis. Primers 4, 18016 (2018).

    PubMed  PubMed Central  Google Scholar 

  204. 204.

    Nelson, J. E., Brunt, E. M. & Kowdley, K. V. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology 56, 1730–1740 (2012).

    CAS  PubMed  Google Scholar 

  205. 205.

    Qi, J., Kim, J. W., Zhou, Z., Lim, C. W. & Kim, B. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. Am. J. Pathol. 190, 68–81 (2020).

    CAS  PubMed  Google Scholar 

  206. 206.

    Tsurusaki, S. et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 10, 449 (2019).

    PubMed  PubMed Central  Google Scholar 

  207. 207.

    Wachenfeld, C. et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur. J. Endocrinol. 145, 335–341 (2001).

    CAS  PubMed  Google Scholar 

  208. 208.

    Reincke, M. et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 78, 790–794 (1994).

    CAS  PubMed  Google Scholar 

  209. 209.

    Saeger, W. et al. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. Hum. Pathol. 34, 180–186 (2003).

    CAS  PubMed  Google Scholar 

  210. 210.

    Giordano, T. J. et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668–676 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  211. 211.

    Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 30, 363 (2016).

    CAS  PubMed  Google Scholar 

  212. 212.

    de Cubas, A. A. et al. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers. Clin. Cancer Res. 21, 3020–3030 (2015).

    PubMed  Google Scholar 

  213. 213.

    Khosla, S. et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J. Clin. Invest. 87, 1691–1699 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  214. 214.

    Fankhauser, M. et al. Synergistic highly potent targeted drug combinations in different pheochromocytoma models including human tumor cultures. Endocrinology 160, 2600–2617 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  215. 215.

    Velasquez, G. et al. The “ring sign” of necrotic pheochromocytoma. Radiology 131, 69–71 (1979).

    CAS  PubMed  Google Scholar 

  216. 216.

    Short, I. A. & Padfield, P. L. Malignant phaeochromocytoma with severe constipation and myocardial necrosis. Br. Med. J. 2, 793–794 (1976).

    CAS  PubMed  PubMed Central  Google Scholar 

  217. 217.

    Delaney, J. P. & Paritzky, A. Z. Necrosis of a pheochromocytoma with shock. N. Engl. J. Med. 280, 1394–1395 (1969).

    CAS  PubMed  Google Scholar 

  218. 218.

    Nyman, D. & Wahlberg, P. Necrotic phaeochromocytoma with gastric haemorrhage, shock, and uncommonly high catecholamine excretion. Acta Med. Scand. 187, 381–383 (1970).

    CAS  PubMed  Google Scholar 

  219. 219.

    Carpenter, A. A. & Kunin, A. S. Pheochromocytoma with acute tubular necrosis. Report of a case. N. Engl. J. Med. 265, 986–988 (1961).

    CAS  PubMed  Google Scholar 

  220. 220.

    Liu, C. L. et al. Targeting the pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells. Mol. Cell. Endocrinol. 499, 110595 (2020).

    CAS  PubMed  Google Scholar 

  221. 221.

    Iannetti, A. et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl Acad. Sci. USA 105, 14058–14063 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  222. 222.

    Riegman, M., Bradbury, M. S. & Overholtzer, M. Population dynamics in cell death: mechanisms of propagation. Trends Cancer 5, 558–568 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  223. 223.

    Vanden Berghe, T. et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods 61, 117–129 (2013).

    CAS  PubMed  Google Scholar 

  224. 224.

    Howard, S. C., Jones, D. P. & Pui, C. H. The tumor lysis syndrome. N. Engl. J. Med. 364, 1844–1854 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references


A.L. is supported by a Heisenberg-Professorship granted by the German Research Foundation (DFG), project number 324141047. Work in the Linkermann Lab and the Bornstein Lab is funded by Medical Clinic 3, University Hospital Carl Gustav Carus Dresden, Germany, and supported by the SFB-TRR 205, SFB-TRR 127 and the international research training group (IRTG) 2251. This work was further supported by the transCampus to S.R.B. and A.L.. N.P.K. was supported by the DFG, project KR3363/3-1. F.B. is supported by the Hochschulmedizin Zürich through the Flagship project Immuno-TarGET. We would like to thank all members of the Linkermann Lab for the ongoing discussions. We cordially thank R. Drtina for her assistance with preparing the first draft of the manuscript.

Author information




W.T., A.B. and A.L. researched data for the article, contributed to the discussion of the content, wrote the article, and reviewed and/or edited the article before submission. F.B., G.E., M.F., M.K., N.P.K., M.R. and S.R.B. researched data for the article, contributed to the discussion of the content, and reviewed and/or edited the article before submission.

Corresponding author

Correspondence to Andreas Linkermann.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information

Nature Reviews Endocrinology thanks J. Yuan and N. Chattipakorn and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tonnus, W., Belavgeni, A., Beuschlein, F. et al. The role of regulated necrosis in endocrine diseases. Nat Rev Endocrinol 17, 497–510 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing